Clinical Trial Detail

NCT ID NCT01799889
Title A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gilead Sciences
Indications

mantle cell lymphoma

diffuse large B-cell lymphoma

B-cell lymphoma

chronic lymphocytic leukemia

Therapies

Entospletinib

Age Groups: adult

No variant requirements are available.